Citius Pharmaceuticals (CTXR) Change in Account Payables (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 17 years of Change in Account Payables data on file, last reported at -$1.6 million in Q1 2026.

• Quarterly Change in Account Payables fell 178.22% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85569.0 (down 98.72% YoY) and the FY2025 annual result came in at $8.8 million, up 338.35% from the prior year.
• Change in Account Payables grew to -$1.6 million in Q1 2026, from -$2.7 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.6 million in Q3 2025 to a low of -$2.7 million in Q4 2025.
• A 5-year average of $450858.8 and a median of $22256.0 in 2024 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables slumped 577.0% — and 2025, when it jumped 8904.83%.
• Tracing CTXR's Change in Account Payables over 5 years: stood at $372200.0 in 2022, then plunged by 175.25% to -$280083.0 in 2023, then jumped by 970.07% to $2.4 million in 2024, then sank by 209.66% to -$2.7 million in 2025, then soared by 41.34% to -$1.6 million in 2026.
• The last three Change in Account Payables figures came in at -$1.6 million (Q1 2026), -$2.7 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.